- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Wockhardt Limited — Updates, 27-01-2026: Press Release
27-01-2026 | 09:05 am
27-01-2026 | 09:05 am
Wockhardt's novel antibiotic Foviscu® (WCK 4282) succeeded in Phase 3 trials for complicated UTIs, matching gold-standard Meropenem. This strengthens its pipeline, offering a key alternative against rising resistance in an Indian market with ~6.5 Cr annual similar drug treatments.
No comments yet. Be the first to comment!